211 related articles for article (PubMed ID: 30485173)
1. Danger of false negative (exclusion) or false positive (diagnosis) for 'congenital thrombophilia' in the age of anticoagulants.
Favaloro EJ
Clin Chem Lab Med; 2019 May; 57(6):873-882. PubMed ID: 30485173
[TBL] [Abstract][Full Text] [Related]
2. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology.
Favaloro EJ; Bonar R; Sioufi J; Wheeler M; Low J; Aboud M; Duncan E; Smith J; Exner T; Lloyd J; Marsden K;
Semin Thromb Hemost; 2005 Feb; 31(1):49-58. PubMed ID: 15706475
[TBL] [Abstract][Full Text] [Related]
3. Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives.
Favaloro EJ; Mohammed S; Curnow J; Pasalic L
Pathology; 2019 Apr; 51(3):292-300. PubMed ID: 30665674
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory.
Siriez R; Dogné JM; Gosselin R; Laloy J; Mullier F; Douxfils J
Int J Lab Hematol; 2021 Feb; 43(1):7-20. PubMed ID: 32946681
[TBL] [Abstract][Full Text] [Related]
5. A 9-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations.
Favaloro EJ; Orsag I; Bukuya M; McDonald D
Pathology; 2002 Aug; 34(4):348-55. PubMed ID: 12190294
[TBL] [Abstract][Full Text] [Related]
6. DOAC-Remove abolishes the effect of direct oral anticoagulants on activated protein C resistance testing in real-life venous thromboembolism patients.
Kopytek M; Ząbczyk M; Malinowski KP; Undas A; Natorska J
Clin Chem Lab Med; 2020 Feb; 58(3):430-437. PubMed ID: 31539350
[TBL] [Abstract][Full Text] [Related]
7. Laboratory diagnosis of hereditary thrombophilia.
Michiels JJ; Hamulyák K
Semin Thromb Hemost; 1998; 24(4):309-20. PubMed ID: 9763348
[TBL] [Abstract][Full Text] [Related]
8. Direct Oral Anticoagulants in Patients with Thrombophilia: Challenges in Diagnostic Evaluation and Treatment.
Undas A; Góralczyk T
Adv Clin Exp Med; 2016; 25(6):1321-1330. PubMed ID: 28028988
[TBL] [Abstract][Full Text] [Related]
9. A multi-laboratory assessment of congenital thrombophilia assays performed on the ACL TOP 50 family for harmonisation of thrombophilia testing in a large laboratory network.
Favaloro EJ; Mohammed S; Vong R; Chapman K; Swanepoel P; Kershaw G; Cai N; Just S; Connelly L; Brighton T; Pasalic L
Clin Chem Lab Med; 2021 Sep; 59(10):1709-1718. PubMed ID: 34116591
[TBL] [Abstract][Full Text] [Related]
10. A clinical audit of congenital thrombophilia investigation in tertiary practice.
Favaloro EJ; Mohammed S; Pati N; Ho MY; McDonald D
Pathology; 2011 Apr; 43(3):266-72. PubMed ID: 21436638
[TBL] [Abstract][Full Text] [Related]
11. The impact of oral anticoagulant therapy, factor VIII level and quality of factor V-deficient plasma on three commercial methods for activated protein C resistance.
Chitolie A; Lawrie AS; Mackie IJ; Harrison P; Machin SJ
Blood Coagul Fibrinolysis; 2001 Apr; 12(3):179-86. PubMed ID: 11414631
[TBL] [Abstract][Full Text] [Related]
12. Inherited Thrombophilia in the Era of Direct Oral Anticoagulants.
Khider L; Gendron N; Mauge L
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163742
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban Causes Missed Diagnosis of Protein S Deficiency but Not of Activated Protein C Resistance (Factor V Leiden).
Maryamchik E; Rosenbaum MW; Van Cott EM
Arch Pathol Lab Med; 2018 Jan; 142(1):70-74. PubMed ID: 28920711
[TBL] [Abstract][Full Text] [Related]
14. Laboratory testing for activated protein C resistance: rivaroxaban induced interference and a comparative evaluation of andexanet alfa and DOAC Stop to neutralise interference.
Favaloro EJ; Gilmore G; Bonar R; Dean E; Arunachalam S; Mohammed S; Baker R
Clin Chem Lab Med; 2020 Jul; 58(8):1322-1331. PubMed ID: 32126010
[TBL] [Abstract][Full Text] [Related]
15. The effect of lupus anticoagulant in the second-generation assay for activated protein C resistance.
Ragland BD; Reed CE; Eiland BM; Tichenor PH; Hudson CL; Fritsma GA; Adler BK; Marques MB
Am J Clin Pathol; 2003 Jan; 119(1):66-71. PubMed ID: 12520699
[TBL] [Abstract][Full Text] [Related]
16. Activated Factor X-Based versus Thrombin-Based Antithrombin Testing in Thrombophilia Workup in the DOAC Era.
Rühl H; Reda S; Müller J; Oldenburg J; Pötzsch B
Thromb Haemost; 2018 Feb; 118(2):381-387. PubMed ID: 29378360
[TBL] [Abstract][Full Text] [Related]
17. Multilaboratory testing in thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation) Quality Assurance Program.
Jennings I; Kitchen S; Woods TA; Preston FE
Semin Thromb Hemost; 2005 Feb; 31(1):66-72. PubMed ID: 15706477
[TBL] [Abstract][Full Text] [Related]
18. The use of direct oral anticoagulants in inherited thrombophilia.
Skelley JW; White CW; Thomason AR
J Thromb Thrombolysis; 2017 Jan; 43(1):24-30. PubMed ID: 27734187
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of "APTT vs RVVT" based activated protein C resistance assay in the diagnosis of Factor V Leiden mutation.
Baig MA
Indian J Pathol Microbiol; 2020; 63(2):247-250. PubMed ID: 32317524
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of DOAC Filter, a new device to remove direct oral anticoagulants from plasma samples.
Sevenet PO; Cucini V; Hervé T; Depasse F; Carlo A; Contant G; Mathieu O
Int J Lab Hematol; 2020 Oct; 42(5):636-642. PubMed ID: 32567799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
